Sandoz has become the latest firm to win a European approval for a higher-concentration biosimilar rival to Humira (adalimumab), hot on the heels of a similar approval for the generics and biosimilars giant in the US.
Sandoz Moves Ahead With High-Concentration Adalimumab In Europe
Approval For Humira Rival’s 100mg/ml Formulation Follows FDA Nod Last Month
Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.
